Antibodies to platelet factor 4 - Heparin complex and outcome in hemodialysis patients with diabetes

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 5, 2010, Pages 874-881

  Krane, Vera ^a   Berger, Mario ^a,b   Lilienthal, Jürgen ^c   Winkler, Karl ^d   Schambeck, Christian ^e   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Bornholm Hospital   (Denmark)

^c DATAMAP GmbH   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIBODY; ATORVASTATIN; BLOOD CLOTTING FACTOR; PLACEBO; PLATELET FACTOR 4 HEPARIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STROKE; SUDDEN DEATH;

AGED; ANTIBODIES; ASPIRIN; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; DEATH, SUDDEN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HEPARIN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET FACTOR 4; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952318466     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01170209     Document Type: Article

References (35)

1. US Renal Data System: USRDS 2007 Annual Data Report, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
2. Johnson DW, Craven AM, Isbel NM: Modification of cardiovascular risk in hemodialysis patients: An evidencebased review. Hemodial Int 11: 1-14, 2007 (Pubitemid 46128673)
3. Ronco C, Bowry S, Tetta C: Dialysis patients and cardiovascular problems: Can technology help solve the complex equation? Blood Purif 24: 39-45, 2006 (Pubitemid 41820820)
4. Walenga JM, Jeske WP, Prechel MM, Bakhos M: Newer insights on the mechanism of heparin-induced thrombocytopenia. Semin Thromb Hemost 30[Suppl 1]: 57-67, 2004
5. Warkentin T, Kelton J: Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases, edited by Bounameaux H, New York, Marcel Dekker, 1994, pp 75-127
6. Stribling WK, Slaughter TF, Houle TT, Sane DC: Beyond the platelet count: Heparin antibodies as independent risk predictors. Am Heart J 153: 900-906, 2007
7. Carrier M, Rodger MA, Fergusson D, Doucette S, Kovacs MJ, Moore J, Kelton JG, Knoll GA: Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int 73: 213-219, 2008
8. Mureebe L, Coats RD, Silliman WR, Shuster TA, Nichols WK, Silver D: Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 136: 848-853, 2004 (Pubitemid 39311312)
9. Nakamoto H, Shimada Y, Kanno T, Wanaka K, Matsuo T, Suzuki H: Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int 9[Suppl 1]: S2-S7, 2005 (Pubitemid 41614636)
10. Pena de la Vega L, Miller RS, Benda MM, Grill DE, Johnson MG, McCarthy JT, McBane RD: Association of heparindependent antibodies and adverse outcomes in hemodialysis patients: A population-based study. Mayo Clin Proc 80: 995-1000, 2005
11. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kutemeyer H, Mann JF, Ruf G, Ritz E: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics. Kidney Blood Press Res 27: 259-266, 2004
12. Wanner C, Krane V, Ruf G, Marz W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71: S222-S226, 1999
13. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005 (Pubitemid 41058323)
14. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G: Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7: 667-675, 1996 (Pubitemid 27465998)
15. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9: 1018-1022, 1998 (Pubitemid 28264728)
16. Ritz E, Wanner C: The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 3: 920-929, 2008
17. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, Ritz E: Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 15: 1530-1536, 2004 (Pubitemid 38679677)
18. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A: Anti-platelet factor 4/heparin antibodies from patients with heparininduced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14: 121-129, 2002
19. Chen PS, Chou CC, Tan AY, Zhou S, Fishbein MC, Hwang C, Karagueuzian HS, Lin SF: The mechanisms of atrial fibrillation. J Cardiovasc Electrophysiol 17[Suppl 3]: S2-S7, 2006
20. Khan R, Sheppard R: Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118: 10-24, 2006
21. Williams RT, Damaraju LV, Mascelli MA, Barnathan ES, Califf RM, Simoons ML, Deliargyris EN, Sane DC: Antiplatelet factor 4/heparin antibodies: An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107: 2307-2312, 2003
22. Mattioli AV, Bonetti L, Sternieri S, Mattioli G: Heparininduced thrombocytopenia in patients treated with unfractionated heparin: Prevalence of thrombosis in a 1 year follow-up. Ital Heart J 1: 39-42, 2000
23. Gluckman TJ, Segal JB, Fredde NL, Saland KE, Jani JT, Walenga JM, Prechel MM, Citro KM, Zidar DA, Fox E, Schulman SP, Kickler TS, Rade JJ: Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am J Cardiol 95: 744-747, 2005
24. Asmis LM, Segal JB, Plantinga LC, Fink NE, Kerman JS, Kickler TS, Coresh J, Gardner LB: Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 100: 498-504, 2008
25. Palomo I, Pereira J, Alarcon M, Diaz G, Hidalgo P, Pizarro I, Jara E, Rojas P, Quiroga G, Moore-Carrasco R: Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal 19: 189-195, 2005
26. Adiguzel C, Bansal V, Litinas E, Cunanan J, Iqbal O, Nelson K, Kannan M, Hoppensteadt D, Fareed J: Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Clin Appl Thromb Hemost 15: 145-151, 2009
27. Xiao Z, Visentin GP, Dayananda KM, Neelamegham S: Immune complexes formed following the binding of antiplatelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood 112: 1091-1100, 2008
28. Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C: A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia: Formation of leukocyte-platelet aggregates. Thromb Haemost 85: 1090-1096, 2001
29. Mascelli MA, Deliargyris EN, Damaraju LV, Barnathan ES, Califf RM, Simoons ML, Sane DC: Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J Thromb Thrombolysis 18: 171-175, 2004
30. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999
31. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 74: 1461-1467, 2008
32. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242, 1999
33. Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA: The prevalence of antibodies to the platelet factor 4-heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res 120: 215-220, 2007
34. Narula AS, Jha V, Bali HK, Sakhuja V, Sapru RP: Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren Fail 22: 355-368, 2000
35. Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A: The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 116: 887-891, 2002